Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Mesoblast International Sárl currently manages 8 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 8 distinct examiners, meaning that each pending matter is assigned to a different individual. The 8 pending office actions are spread across 6 distinct art units, which suggests that the filings cover several different technical sub-specialties within the biotechnology field. This distribution requires practitioners to navigate multiple administrative environments simultaneously.
TIWARI, VYOMA SHUBHAM is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. The 8 distinct examiners provide a variety of perspectives on the company patent portfolio, while the 6 distinct art units provide a structured framework for these examinations. With 8 pending office actions in the pipeline, Mesoblast International Sárl maintains an active prosecution pipeline across its primary technology area. Practitioners must coordinate across the 8 distinct examiners to ensure consistent claim strategies.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| Multi-statute (no §101) | 5 (62%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 1 | 31.5% | +48.1% |
| THUESON, HANNA MARIE | 1 | 76.7% | +28.2% |
| GU, QINHUA | 1 | 75.9% | +27.8% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
| SHIBUYA, MARK LANCE | 1 | 32.3% | +24.9% |
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
| TAKENAKA, RISA | 1 | 27.3% | +100.0% |
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041303 | A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE | KIM, TAEYOON | 18d overdue |
| 18001462 | 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | SHIBUYA, MARK LANCE | 17d overdue |
| 18723204 | METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE | TIWARI, VYOMA SHUBHAM | — |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | THUESON, HANNA MARIE | — |
| 17906150 | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE II | CONNORS, ALEXANDRA F | — |
| 17904581 | METHOD FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | TAKENAKA, RISA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041303 | A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE | KIM, TAEYOON | 18d overdue |
| 18001462 | 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | SHIBUYA, MARK LANCE | 17d overdue |
| 17612939 | FUNCTIONAL RECOVERY FROM CEREBRAL INFARCTION | BARRON, SEAN C | 2d overdue |
| 18723204 | METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE | TIWARI, VYOMA SHUBHAM | — |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | THUESON, HANNA MARIE | — |
| 18262505 | OPIOID SPARING COMPOSITIONS AND METHODS OF USING THE SAME | GU, QINHUA | — |
| 17906150 | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE II | CONNORS, ALEXANDRA F | — |
| 17904581 | METHOD FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | TAKENAKA, RISA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1638 | 1 |
| 1633 | 1 |
| 1634 | 1 |
| 1632 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723204 | METHOD OF TREATING SEVERE GRAFT VERSUS HOST DISEASE | TIWARI, VYOMA SHUBHAM | — | §102§103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18556827 | METHOD FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN SPECIFIC PATIENTS USING MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | THUESON, HANNA MARIE | 1638 | §102§103§112 | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18262505 | OPIOID SPARING COMPOSITIONS AND METHODS OF USING THE SAME | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Jul 21, 2023 |
| 18041303 | A COMPOSITION COMPRISING MESENCHYMAL PRECURSOR OR STEM CELLS AND THEIR USE | KIM, TAEYOON | 1631 | §102§103§112Other | Final Rejection | 18d overdue | Pending | Feb 10, 2023 |
| 18001462 | 3D CULTURE OF MESENCHYMAL LINEAGE PRECURSOR OR STEM CELLS | SHIBUYA, MARK LANCE | 1631 | §102§103 | Final Rejection | 17d overdue | Pending | Dec 09, 2022 |
| 17906150 | METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE II | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | — | Pending | Sep 12, 2022 |
| 17904581 | METHOD FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | TAKENAKA, RISA | 1632 | §103Other | Non-Final OA | — | Pending | Aug 18, 2022 |
| 17612939 | FUNCTIONAL RECOVERY FROM CEREBRAL INFARCTION | BARRON, SEAN C | 1653 | §103 | Non-Final OA | 2d overdue | Pending | Nov 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial